First Drugs For Lupus Nephritis Are Headed For US FDA Review
Two drugs that would be the first for lupus nephritis are on the doorstep of the US FDA, a novel drug voclosporin from Aurinia Pharmaceuticals and Benlysta from GlaxoSmithKline.
You may also be interested in...
Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
Keeping Track: Myovant, Almirall, MacroGenics Nab Novel Approvals; Novartis’ Inclisiran Delayed
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
GSK's Eyes Benlysta Expansion With First US FDA Lupus Nephritis Approval
The new indication paves the way for Benlysta in a new patient population, as well as expansion in systemic lupus erythematosus, US specialty unit head Sheri Mullen said.